A Prospective, Multicenter, Open-Label Study of Dose Escalation Therapy in Male Patients With Nocturia Refractory to 0.2-mg Tamsulosin Monotherapy
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To investigate the efficacy and safety of 0.4 mg of tamsulosin in patients with nocturia not responding to 0.2 mg. Methods: Patients with intractable nocturia after treatment with 0.2 mg of tamsulosin for>1 month were included in a multicenter, prospective, observational, single-arm study. Patients were prescribed 0.4 mg of tamsulosin and followed up for 2 months to assess nocturnal voiding and nocturia-related bother. Changes in the mean number of nocturnal voids, the proportion of 50% responders, 3-day frequency-volume chart parameters, and questionnaire scores were assessed. Results: Sixty-two patients were prescribed 0.2 mg of tamsulosin, of whom 56 were prescribed 0.4 mg of tamsulosin. Ten patients dropped out. A single case of orthostatic hypotension was reported. The mean age was 68 years. After 1 and 2 months of taking 0.4 mg of tamsulosin, 23.9% and 22.7% of patients demonstrated a>50% reduction of nocturia, and 16.1% and 19.4% of patients rated the treatment as “very effective,” respectively. Dose escalation to 0.4 mg of tamsulosin, compared to 0.2 mg, did not show an additional effect on reducing nocturnal urine volume. Multivariate logistic regression analysis showed that lower serum sodium levels (odds ratio [OR], 0.41, P=0.037) and the presence of urge incontinence (OR, 7.08, P=0.036) were predictors of a significant improvement of nocturia in response to 0.4 mg of tamsulosin. Conclusions: Dose escalation may yield a significant improvement of nocturia in>20% of patients, and may be especially helpful in patients with lower sodium levels and urge incontinence.
Abstract
Purpose: To investigate the efficacy and safety of 0.4 mg of tamsulosin in patients with nocturia not responding to 0.2 mg. Methods: Patients with intractable nocturia after treatment with 0.2 mg of tamsulosin for>1 month were included in a multicenter, prospective, observational, single-arm study. Patients were prescribed 0.4 mg of tamsulosin and followed up for 2 months to assess nocturnal voiding and nocturia-related bother. Changes in the mean number of nocturnal voids, the proportion of 50% responders, 3-day frequency-volume chart parameters, and questionnaire scores were assessed. Results: Sixty-two patients were prescribed 0.2 mg of tamsulosin, of whom 56 were prescribed 0.4 mg of tamsulosin. Ten patients dropped out. A single case of orthostatic hypotension was reported. The mean age was 68 years. After 1 and 2 months of taking 0.4 mg of tamsulosin, 23.9% and 22.7% of patients demonstrated a>50% reduction of nocturia, and 16.1% and 19.4% of patients rated the treatment as “very effective,” respectively. Dose escalation to 0.4 mg of tamsulosin, compared to 0.2 mg, did not show an additional effect on reducing nocturnal urine volume. Multivariate logistic regression analysis showed that lower serum sodium levels (odds ratio [OR], 0.41, P=0.037) and the presence of urge incontinence (OR, 7.08, P=0.036) were predictors of a significant improvement of nocturia in response to 0.4 mg of tamsulosin. Conclusions: Dose escalation may yield a significant improvement of nocturia in>20% of patients, and may be especially helpful in patients with lower sodium levels and urge incontinence.
참고문헌 (22)
- Choo MS, "Prevalence of nocturia in a Korean population aged 40 to 89 years", Neurourol Urodyn, 27, pp.60~64 (2008)
- Weiss JP, "Nocturia", J Urol, 163, pp.5~12 (2000)
- 강동일, "Short Term Effect and Safety of Antidiuretic Hormone in the Patients with Nocturia", International Neurourology Journal, 14(4), pp.227~231 (2010), 대한배뇨장애요실금학회
- Wang CJ, "Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia : a double-blind, placebo controlled, randomized study", J Urol, 185, pp.219~223 (2011)
- Park CH, "Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a nonblind multicentre korean study", Clin Drug Investig, 24, pp.41~47 (2004)
- 김수진, "Evidence Is Enough?: A Systematic Review and Network Meta- Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients", International Neurourology Journal, 21(1), pp.29~37 (2017), 대한배뇨장애요실금학회
- Bae WJ, "Desmopressin add-on therapy for refractory nocturia in men receiving α-blockers for lower urinary tract symptoms", J Urol, 190, pp.180~186 (2013)
- 차우헌, "Comparison and Efficacy of Low-Dose and Standard-Dose Tamsulosin and Alfuzosin in Medical Expulsive Therapy for Lower Ureteral Calculi: Prospective, Randomized, Comparative Study", Investigative and Clinical Urology, 53(5), pp.349~354 (2012), 대한비뇨의학회[DOI]
- Kojima Y, "Tamsulosin reduces nighttime urine production in benign prostatic hyperplasia patients with nocturnal polyuria : a prospective open-label long-term study using frequency-volume chart", Neurourol Urodyn, 31, pp.80~85 (2012)
- 이효석, "Efficacy and Safety of Tamsulosin for Treating Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled, Open-Label Non-Inferiority Study", Investigative and Clinical Urology, 53(3), pp.178~183 (2012), 대한비뇨의학회
- Zhang K, "Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2mg on nocturia in Chinese men with lower urinary tract symptoms:a prospective, multicenter, randomized, open, parallel study", Urology, 78, pp.636~640 (2011)
- Yoshida M, "Effectiveness of tamsulosin hydrochloride and its mechanism in improving nocturia associated with lower urinary tract symptoms", benign prostatic hyperplasia, 2010, pp.29, 1276~1281
- Gorgel SN, "The effect of combined therapy with tamsulosin hydrochloride and meloxicam in patients with benign prostatic hyperplasia symptoms and impact on nocturia and sleep quality", Int Braz J Urol, 39, pp.657~662 (2013)
- Simaioforidis V, "Tamsulosin versus transurethral resection of the prostate : effect on nocturia as a result of benign prostatic hyperplasia", Int J Urol, 18, pp.243~248 (2011)
- Paick JS, "The role of prolactin levels in the sexual activity of married men with erectile dysfunction", BJU Int, 98, pp.1269~1273 (2006)
- Johnson TM 2nd, "The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia", J Urol, 178, pp.2045~2050 (2007)
- Roehrborn CG, "Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia : a pooled analysis of three double-blind, placebo-controlled studies", BJU Int, 92, pp.257~261 (2003)
- Villalobos-Molina R, "Alpha 1D-and alpha 1A-adrenoceptors mediate contraction in rat renal artery", Eur J Pharmacol, 322, pp.225~227 (1997)
- Armenia A, "Functional subtypes of renal alpha1-adrenoceptor in diabetic and nondiabetic 2K1C Goldblatt renovascular hypertension", Acta Pharmacol Sin, 29, pp.564~572 (2008)
- Yoshimura K, "Nocturia and benign prostatic hyperplasia", Urology, 61, pp.786~790 (2003)
- Tyagi S, "Nocturnal polyuria in older women with urge urinary incontinence: role of sleep quality, time in bed and medications used", J Urol, 197(3Pt 1), pp.753~758 (2017)
- Filippatos TD, "Hyponatremia in the elderly : challenges and solutions", Clin Interv Aging, 12, pp.1957~1965 (2017)